Program
paliperidone
Also written as “Paliperidone ER”, “Paliperidone” and “Paliperidone palmitate”.
Its studies are mostly in Schizophrenia · Psychotic Disorders · Bipolar Disorder · Psychomotor Agitation, led by 4 companies.
Drug pagePaliperidone: every studyAll 136 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 1000 open or running | phase 4since Aug 30, 2007 | Nov 19, 2003 | none ahead |
| Luye Pharma Groupits history only | 30 open or running | phase 1since May 8, 2020 | May 8, 2020 | none ahead |
| CSPC Pharmaceutical Group | 21 open or running | no phasesince Sep 30, 2025 | Sep 30, 2025 | Dec 31, 2026NCT07493551 |
| Pharmathenits history only | 10 open or running | phase 2since Jan 26, 2018 | Jan 26, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2025First study: no phase study in SchizophreniaFirst studyNCT07268430 · 256 enrolled · China
- Mar 4, 2026No phase study in SchizophreniaNCT07493551 · 260 planned · China
Ahead
- Dec 31, 2026Primary completion: no phase study in SchizophreniaNCT07493551
TargetBeta
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07493551Schizophrenia · China | – | Recruiting | Dec 31, 2026 | 260 |
| NCT07268430Schizophrenia · China | – | Completed | Dec 25, 2024 | 256 |
How it is read
Names in the registry
- “Paliperidone ER”, 39 entries
- “Paliperidone”, 13 entries
- “Paliperidone palmitate”, 10 entries
- “paliperidone palmitate”, 7 entries
- “Paliperidone Palmitate”, 6 entries
Conditions, from the studies’ own filings
- Schizophrenia, 95 studies
- Psychotic Disorders, 4 studies
- Bipolar Disorder, 4 studies
- Psychomotor Agitation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.